Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifampicin and albendazole exploratory efficacy study for onchocerciasis in loiasis co-endemic areas
PACTR202212910949177Phase 2Recruiting
- Sponsor
- University of Buea
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of rifampicin and albendazole in onchocerciasis (10 arms), sponsored by University of Buea. Primary endpoints: Female worm embryogenesis status and Wolbachia load. Started Feb 2023; status: recruiting.
02
Drugs
rifampicinalbendazole
03
Conditions
onchocerciasis
Beyond the preview
Go deeper on PACTR202212910949177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202212910949177.